BTIG lowered the firm’s price target on Cryoport (CYRX) to $10 from $13 and keeps a Buy rating on the shares following the firm’s survey of biopharma manufacturers. R&D Services budgets will likely face the most risk and headwinds over the next 2 years, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX:
- CryoPort Sells CRYOPDP Business to DHL Group
- CryoPort Holds 2025 Annual Stockholders Meeting
- Cryoport Inc’s Earnings Call Highlights Growth and Partnerships
- CryoPort’s Strong Performance and Growth Potential Justifies Buy Rating Despite Macroeconomic Challenges
- Cryoport Reports Strong Start to 2025 with Revenue Growth